Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.
Chen
Ming Hui
MH
Cardiology Department, Children's Hospital Boston, Boston, Mass., USA.
Kerkelä
Risto
R
Force
Thomas
T
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases